Monday, June 30, 2025 6/30/2025

Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment

Award Number: R01CA269221
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment - ABSTRACT Malignant melanoma is the most lethal form of skin cancer with an increasing incidence in the United States. Unfortunately, no curative treatment exists for metastatic melanoma. Despite the significant advances of molecularly targeted treatments (BRAF-, CTLA-4- and PD-1-targeted therapies) in treating metastatic melanoma over the past decade, the 5-year survival is only 35% for metastatic melanoma patients. Thus, there is an urgent need to develop alternative treatment strategies for metastatic melanoma. Melanocortine-1 receptor (MC1R) is a distinct molecular target due to its high expression in >80% of melanotic and amelanotic human metastatic melanoma. Our remarkable first-in-human results clearly demonstrate the feasibility of using MC1R-targeted 68Ga-DOTA-GGNle-CycMSHhex for human melanoma imaging. Recently, we have identified DOTA-GGNle-CycMSHhex(KD) peptide with 0.12 nM MC1R binding affinity which is dramatically improved by 8.3-fold as compared to DOTA-GGNle-CycMSHhex. Moreover, the replacement of -GG- with 8-Aminooctanoic acid (-Aoc-) linker further improves the MC1R binding affinity of DOTA-AocNle-CycMSHhex(KD) peptide by 3.8-fold as compared to DOTA-GGNle-CycMSHhex(KD). Thus, we propose to develop novel theranostic 203Pb/212Pb-DOTA-Linker-Nle-CycMSHhex(KD) peptides for imaging- guided MC1R-targeted alpha radionuclide therapy (MC1R-TART), and combine them with immune checkpoint inhibitors (ICIs) for melanoma treatment in this project. We hypothesize that novel theranostic 203Pb/212Pb- DOTA-Linker-Nle-CycMSHhex(KD) peptides can be used for imaging-guided MC1R-TART, and the combinations of MC1R-TART and ICIs can treat melanoma more effectively than MC1R-TART only. The objective of this project is to develop novel theranostic 203Pb/212Pb-DOTA-Linker-Nle-CycMSHhex(KD) peptides imaging-guided MC1R-TART, and combine MC1R-TART with ICIs for melanoma treatment. Our awarded US patents clearly demonstrate the originality and novelty of this project. Our positive preliminary results strongly support our hypothesis and research design. Importantly, we have assembled a strong research team with established expertise that is uniquely suited to carry out this exciting translational project. The positive results of this project will demonstrate the feasibility and efficacy of combining MC1R-TART and ICIs for melanoma treatment, and provide a new insight into the design of novel treatments for metastatic melanoma. The success of this project will provide clinicians a novel valuable imaging tool (203Pb-peptide) to identify MC1R-positive patients who will benefit from the treatments, determine patient-specific dosimetry for safe and efficacious doses, and monitor patients’ responses to MC1R-TART and ICIs treatments. The success of this project will pave the way for evaluating this novel treatment in future FDA-approved clinical trials, provide patients with personalized diagnoses and treatments, enhancing the opportunity for cure to metastatic melanoma patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $557,992 )
2025	2025	THE REGENTS OF THE UNIV. OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Cancer Treatment Research	000	3	3/5/2025	NON-COMPETING CONTINUATION	$557,992
														Subtotal = $557,992

Issue Date FY: 2024 ( Subtotal = $601,253 )
2024	2024	THE REGENTS OF THE UNIVERSITY OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Cancer Treatment Research	000	2	2/2/2024	NON-COMPETING CONTINUATION	$569,607
2024	2024	THE REGENTS OF THE UNIVERSITY OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Cancer Treatment Research	001	2	4/25/2024	NON-COMPETING CONTINUATION	$31,646
														Subtotal = $601,253

Issue Date FY: 2023 ( Subtotal = $639,351 )
2023	2023	REGENTS OF THE UNIVERSITY OF COLORADO, THE	13001 E 17TH PLACE F428	AURORA	CO	80045	ADAMS	USA	Cancer Treatment Research	000	1	3/27/2023	NEW	$639,351
														Subtotal = $639,351

Grand Total All Awards = $1,798,596

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Combinations of Receptor-Targeted Alpha Radionuclide Therapy and Immune Checkpoint Inhibitors for Melanoma Treatment

Award Number: R01CA269221

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer